Revenue: As of FY2025 Q3, the actual value is USD 83.52 M.EPS: As of FY2025 Q3, the actual value is USD 0.1.EBIT: As of FY2025 Q3, the actual value is USD 8.118 M.<h3>Segment Revenue</h3><ul><li>Prenatal: Revenue for the three months ended September 30, 2025 was $74.1 million, compared to $36.6 million for the same period in 2024. For the nine months ended September 30, 2025, revenue was $191.0 million, compared to $102.7 million in 2024.</li><li>Oncology: Revenue for the three months ended September 30, 2025 was $8.7 million, compared to $1.1 million for the same period in 2024. For the nine months ended September 30, 2025, revenue was $15.8 million, compared to $1.9 million in 2024.</li><li>Clinical Trial Support and Other Services: Revenue for the three months ended September 30, 2025 was $0.8 million, compared to $0.7 million for the same period in 2024. For the nine months ended September 30, 2025, revenue was $2.2 million, compared to $3.0 million in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: For the three months ended September 30, 2025, net income was $5.7 million, compared to a net loss of $14.9 million for the same period in 2024. For the nine months ended September 30, 2025, net income was $1.5 million, compared to a net loss of $30.1 million in 2024.</li><li>Gross Margin: Gross margin for the three months ended September 30, 2025 was 70%, compared to 53% for the same period in 2024. For the nine months ended September 30, 2025, gross margin was 67%, compared to 51% in 2024.</li><li>Operating Profit: Income from operations for the three months ended September 30, 2025 was $9.6 million, compared to a loss of $12.6 million for the same period in 2024. For the nine months ended September 30, 2025, income from operations was $5.7 million, compared to a loss of $35.5 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Cash provided by operating activities during the nine months ended September 30, 2025 was $13.8 million, compared to cash used in operating activities of $32.9 million during the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Total Test Volume: Approximately 162,900 tests for the three months ended September 30, 2025, compared to 107,900 for the same period in 2024. Approximately 440,500 tests for the nine months ended September 30, 2025, compared to 289,900 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue expanding its market acceptance and achieving commercial success in its prenatal and oncology product lines. This includes maintaining and expanding relationships with healthcare providers and increasing payor coverage and reimbursement.</li><li>Non-Core Business: The company is involved in partnerships, such as with Johnson &amp; Johnson, for the development and commercialization of companion diagnostics, which may require FDA approval.</li><li>Priority: Emphasis on increasing ASPs through expanded payor coverage and reimbursement, and improving operational efficiency through automation and AI integration.</li></ul>

Billiontoone | 10-Q: FY2025 Q3 Revenue: USD 83.52 M